OZEMPIC Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving OZEMPIC Growth

1. Market Share Gains and New Patient Starts

• OZEMPIC continues to capture substantial market share across the type 2 diabetes and weight management segments.
• A significant rise in new patient starts, fueled by increasing physician confidence and strong patient demand, is driving prescription growth.
• Novo Nordisk's robust commercial strategy, direct-to-consumer campaigns, and healthcare provider education initiatives are further accelerating adoption.

2. Expansion Across Key Indications

• Type 2 Diabetes: OZEMPIC remains one of the leading GLP-1 receptor agonists for glycemic control, with cardiovascular benefits adding to its value proposition.
• Obesity/Weight Management: Strong off-label and on-label use for weight management is expanding its patient base, supported by favorable real-world outcomes.
• Cardiovascular Risk Reduction: Demonstrated efficacy in reducing major adverse cardiovascular events is boosting adoption in high-risk populations.
• Pipeline Developments: Ongoing trials in non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and heart failure suggest potential future indications that could broaden its market reach.

3. Geographic Expansion

• OZEMPIC is widely available in the US, Europe, and Japan, with expansion continuing into emerging markets.
• The Asia-Pacific region is expected to see the fastest uptake, driven by rising diabetes prevalence, improving access to advanced therapies, and growing obesity awareness.
• Novo Nordisk is enhancing local manufacturing capacity and strengthening distribution networks to meet surging global demand.

4. New Indication Approvals

• Regulatory approvals for expanded use in cardiovascular risk reduction in patients with type 2 diabetes broaden its treatment landscape.
• Ongoing regulatory submissions for obesity-related indications and cardiovascular outcomes will further strengthen positioning.

5. Strong Diabetes and Obesity Volume Momentum

• Type 2 diabetes remains the core growth driver, with consistent double-digit prescription volume increases.
• Obesity care demand is accelerating rapidly, with OZEMPIC often prescribed alongside or as a bridge to Wegovy, reinforcing Novo Nordisk's leadership in the GLP-1 space.
• Novo Nordisk's 2025 updates highlight sustained prescription growth across both diabetes and weight management segments, supported by compelling real-world efficacy data.

6. Competitive Differentiation and Market Trends

• Once-weekly injection profile of OZEMPIC offers superior convenience compared to daily GLP-1 therapies, enhancing adherence.
• Proven cardiometabolic benefits (glycemic control, weight loss, cardiovascular protection) set it apart from many competing antidiabetic drugs.
• Broader market trends such as the shift toward obesity care, personalized medicine, and cardiometabolic risk management strongly support OZEMPIC's positioning.
• Growing reliance on Real-World Evidence (RWE) and long-term outcomes data is reinforcing payer confidence and expanding reimbursement coverage.
• The increasing move toward combination therapies and oral GLP-1 formulations (e.g., Rybelsus) further complements OZEMPIC's role in Novo Nordisk's portfolio.

OZEMPIC Recent Developments

• In September 2025, Novo Nordisk announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, OZEMPIC (once-weekly injectable semaglutide) was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23%. The data span nearly 60,000 US Medicare patients (aged >=66 years) living with type 2 diabetes, atherosclerotic cardiovascular disease (ASCVD) - a condition where fatty deposits build up in blood vessels, reducing blood flow and increasing the risk of heart attacks, strokes and related problems - and multiple health conditions. The results were presented at the European Association for the Study of Diabetes (EASD) 2025.
• In August 2025, Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved OZEMPIC (semaglutide) for USD 499 per month, as part of the company's ongoing effort to explore new collaborations and approaches to improving access to authentic semaglutide medicines. This offer is available through multiple platforms to eligible patients with a prescription for OZEMPIC and aims to assist type 2 diabetes patients who may potentially face prices at or above wholesale cost that are uninsured or choose to self-pay.
• In June 2025, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for an update of the OZEMPIC (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

"OZEMPIC Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of OZEMPIC for approved indications like type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus in the 7MM. A detailed picture of OZEMPIC's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the OZEMPIC for approved and potential indications. The OZEMPIC market report provides insights about OZEMPIC's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OZEMPIC performance, future market assessments inclusive of the OZEMPIC market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OZEMPIC sales forecasts, along with factors driving its market.

OZEMPIC Drug Summary

OZEMPIC (semaglutide) injection 0.25 mg, 0.5 mg, 1.0 mg or 2.0 mg is a once-weekly GLP-1 RA indicated, along with diet and exercise, to improve blood sugar (glucose) in adults with type 2 diabetes and to reduce the risk of major CV events such as heart attack, stroke or death in adults with type 2 diabetes mellitus with known heart disease. OZEMPIC is the only GLP-1 RA indicated to reduce the risk of worsening kidney disease and risk of death from CV events in adults with type 2 diabetes and CKD. OZEMPIC is currently marketed in 72 countries, and 7 million people with type 2 diabetes are currently being treated with OZEMPIC worldwide. The report provides OZEMPIC's sales, growth barriers and drivers, post usage and approvals in multiple indications.

OZEMPIC is in the Phase III stage of clinical development for the treatment of patients with Alzheimer's disease (NCT04777396) and Peripheral Arterial Disease (NCT04560998); in Phase II stage for Liver Cirrhosis (NCT03987451); and in Phase I stage for type 1 diabetes mellitus (NCT07087795).

Scope of the OZEMPIC Market Report

The report provides insights into:

• A comprehensive product overview including the OZEMPIC MoA, description, dosage and administration, research and development activities in approved indications like type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus.
• Elaborated details on OZEMPIC regulatory milestones and other development activities have been provided in OZEMPIC market report.
• The report also highlights OZEMPIC's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The OZEMPIC market report also covers the patents information, generic entry and impact on cost cut.
• The OZEMPIC market report contains current and forecasted OZEMPIC sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OZEMPIC market report also features the SWOT analysis with analyst views for OZEMPIC in approved and potential indications.

Methodology:

The OZEMPIC market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OZEMPIC Analytical Perspective by DelveInsight

• In-depth OZEMPIC Market Assessment

This OZEMPIC sales market forecast report provides a detailed market assessment of OZEMPIC for approved indications like type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OZEMPIC sales data uptil 2034.

• OZEMPIC Clinical Assessment

The OZEMPIC market report provides the clinical trials information of OZEMPIC for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OZEMPIC Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OZEMPIC Market Potential & Revenue Forecast

• Projected market size for the OZEMPIC and its key indications
• Estimated OZEMPIC sales potential (OZEMPIC peak sales forecasts)
• OZEMPIC Pricing strategies and reimbursement landscape

OZEMPIC Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OZEMPIC Market positioning compared to existing treatments
• OZEMPIC Strengths & weaknesses relative to competitors

OZEMPIC Regulatory & Commercial Milestones

• OZEMPIC Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OZEMPIC Clinical Differentiation

• OZEMPIC Efficacy & safety advantages over existing drugs
• OZEMPIC Unique selling points

OZEMPIC Market Report Highlights

• In the coming years, the OZEMPIC market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OZEMPIC companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OZEMPIC's dominance.
• Other emerging products for type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus are expected to give tough market competition to OZEMPIC and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OZEMPIC in approved and potential indications.
• Analyse OZEMPIC cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OZEMPIC sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OZEMPIC in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of OZEMPIC? How strong is OZEMPIC's clinical and commercial performance?
• What is OZEMPIC's clinical trial status in each individual indications such as type 2 diabetes, obesity, chronic kidney disease, metabolic-associated steatohepatitis (MASH); as well as potential indications like peripheral arterial disorders, alzheimer's disease, liver cirrhosis, and type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OZEMPIC Manufacturers?
• What are the key designations that have been granted to OZEMPIC for approved and potential indications? How are they going to impact OZEMPIC's penetration in various geographies?
• What is the current and forecasted OZEMPIC market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OZEMPIC in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OZEMPIC for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is OZEMPIC? What is the duration of therapy and what are the geographical variations in cost per patient?